

# Original Article

# Evaluation of epidemiological and microbiological characteristics, clinical features, and outcomes of adult patients with infective endocarditis in Mashhad, Iran

Ali Shahini<sup>1</sup>, Matin Shirazinia<sup>1</sup>, Raha Jafari<sup>2</sup>, Ali Akbar Heydari<sup>3</sup>

- <sup>1</sup> Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
- <sup>2</sup> Department of Medicine, Mashhad Medical Sciences Branch, Islamic Azad University, Mashhad, Iran
- <sup>3</sup> Research Center for Infection Control & Hand Hygiene, Department of Infectious Diseases, Imam Reza Hospital, , Mashhad University of Medical Sciences, Mashhad, Iran

#### **Abstract**

Introduction: Infective endocarditis (IE) is a serious problem with high morbidity and mortality. However, there is a paucity of data regarding its epidemiology in non-high-income settings. Here, we described the characteristics of patients with IE.

Methodology: Between March 2012 to March 2020, all adults (≥ 16 years) with a diagnosis of IE who were admitted to a university hospital in Mashhad, Iran, were included in the study.

Results: We evaluated 46 cases of IE with a median age of 42 years (interquartile range 31 to 58.3 years), of whom 21 (46%) had a definite diagnosis. The presence of a prosthetic valve or intracardiac device was the leading predisposing factor (N = 14, 30%). The etiology of IE in 22 subjects (48%) remained unknown. *Staphylococcus aureus* (N = 12, 26%) was the most common causative pathogen. Echocardiography revealed the mitral valve as the most affected valve (N = 18, 39%). Intravenous drug users (IVDU) had a higher chance of right-sided IE, as compared to no IVDU patients (odds ratio: 35, 95% CI: 3.7 to 425.0). The most prevalent complications were lung infarction, acute heart failure, and neurologic involvement (N = 5, 11% for each), and 15 patients (33%) died because of IE.

Conclusions: In our study, the median age of IE onset was relatively low. The most frequent predisposing factor was a prosthetic valve or intracardiac device. The proportion of negative blood cultures was unacceptably high. Thus, our findings emphasize promoting laboratory infrastructure, developing a national protocol for early initiation of appropriate treatment, and eliminating predisposing factors.

**Key words:** Infective endocarditis; epidemiology; microbiology; outcome.

J Infect Dev Ctries 2023; 17(9):1330-1336. doi:10.3855/jidc.17583

(Received 24 October 2022 - Accepted 26 March 2023)

Copyright © 2023 Shahini *et al*. This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

### Introduction

Infective endocarditis (IE) is the infection of the endocardium that affects a small number of people but has high morbidity and mortality [1]. During the past three decades, the incidence of IE and its mortality rate have been steadily rising, particularly in areas with a higher socio-demographic Index (SDI). In 2019, it was anticipated that there were 1,090,527 incident cases of IE worldwide, which resulted in 66,322 fatalities and 1,723,594 disability-adjusted life years [2]. Despite advancements in medical and surgical treatment, IE remains a fatal condition with significant mortality rates, which range from 14 to 22 percent in-hospital and reach 51 percent after ten years [3]. Moreover, the population at risk of IE has increased during previous decades because of several factors, including population aging, the rise in the number of patients receiving hemodialysis for end-stage renal disease, an increase in the usage of cardiac implantable electronic

devices, and the increased number of patients with congenital heart disease who survive to adulthood [3–5]. Also, alterations in the disease's microbiology have taken place worldwide, varying among countries [6,7]. Streptococci species, particularly oral cavity flora, have historically been the predominant bacterial pathogens. However, staphylococcal species, including methicillin-resistant strains (MRSA), now represent a substantial growing portion of IE subjects [8].

In high-income countries, the epidemiologic factors that are engaged in the incidence of IE have altered in comparison to the past few decades due to parameters such as an increased life span, a markedly increased number of nosocomial cases, and an increased number of cases of degenerative valvular disease [9,10]. However, a paucity of data is available in developing countries such as Iran [11–13]. In this regard, we aimed to conduct a retrospective study to determine the demographical, microbiological, clinical features, and

outcomes of patients admitted to a referral hospital in Mashhad, Iran, with a diagnosis of IE between March 2012 to March 2020.


# Methodology

This investigation was a cross-sectional study conducted in the Department of Infectious Diseases between March 2012 to March 2020 on all adults (age 16 or older) with the diagnosis of IE who were admitted to a referral, 1000-bed tertiary care hospital in Mashhad, Iran. First, using ICD-10 codes, patients with a diagnosis of IE were identified. Then, patients' medical records were reviewed to categorize them into definitive and probable based on the modified Duke criteria [7]. Our exclusion criteria were lack or incomplete data regarding the diagnosis of IE (based on the modified Duke criteria), patients younger than 16 years old, and patients with non-infective endocarditis.

Extracted data were gathered using pre-designed checklists. Data comprised demographic features, clinical and laboratory findings, echocardiographic reports, underlying conditions, causative microorganisms (recognized using conventional blood culture and serology), minor and major Duke criteria, and patients' outcomes.

Normality was assessed using Kolmogorov-Smirnov test. Continuous variables were described by median and interquartile range (25th percentile -75th percentile) or mean and standard deviation based on normality. Frequency and percentage were represented as the categorical variables. For univariable analysis,

**Figure 1.** Summary of 55 cases with initial diagnosis of Infective Endocarditis



1 IE: infective myocarditis; 2 Forty-two patients had valvular involvement, of whom one patient with single valve involvement had no data regarding the affected valve; 3 Data regarding the type of surgery were not available for seven of the patients.

the Mann-Whitney U-test (normally distributed data) and independent t-test (not normally distributed data) were used for continuous variables, while the Fisher exact test or the Chi-square test were used for categorical variables, as appropriate. Additionally, we interpreted the strength of association based on Olivier *et al.* study [14]. All data were analyzed using SPSS software (version 23, SPSS Inc., Chicago, IL, USA).

The Ethics Committee of the Mashhad University of Medical Sciences approved this research (ethics code: IR.MUMS.MEDICAL.REC.1398.592).

#### Results

Between March 2012 to March 2020, a total of 55 patients were included in our study based on primary screening. Nine cases were excluded (two did not fulfill the modified Duke criteria for definite or probable IE, six were younger than 16, and one had an alternative diagnosis) (Figure 1). The rest of the 46 patients included in our study (median age (25th percentile to 75th percentile) = 42 years (31 to 58.3)), of whom 29 were males (63%) (Table 1).

The most common patients' comorbidity and underlying valvular disease were ischemic heart disease (N = 10, 22%) and mitral valve regurgitation (N = 7, 20%)

Table 1. Characteristics of the patients with infective endocarditis.

THE CONTROL OF THE CO	
Characteristic	Total, $N = 46$
Age (years), median (25th percentile to 75th	12 (21 to 50 2)
percentile)	42 (31 to 58.3)
Elderly (≥ 60 years, %)	10 (22)
Gender, male (%)	29 (63)
Educational status (%), N = 29	
No former education	5 (17)
Primary education	17 (59)
Diploma	6 (21)
Academic education	1 (4)
Underlying comorbidities (%)	
Ischemic heart disease	10 (22)
Hypertension	9 (20)
Diabetes mellitus	7 (15)
Chronic kidney disease	6 (13)
History of rheumatic heart disease	3 (7)
Obstructive pulmonary disease	2 (4)
History of kidney transplantation	2 (4)
Active cancer	2 (4)
Stroke	2 (4)
HIV/AIDS	1(2)
History of cardiac valve disease (%)	
Mitral valve regurgitation	7 (15)
Mitral valve prolapse	4 (9)
Bicuspid aortic valve	3 (7)
Calcific aortic stenosis	2 (4)
Mitral stenosis	2 (4)
History of central venous catheter (%)	7 (15)
Previous history of IE (%)	7 (15)

15%), respectively. A previous episode of IE and a history of central venous catheterization were presented each in seven (15%). Thirty-eight cases (83%) had at least one predisposing factor for IE. The presence of a prosthetic valve or intracardiac device was the most common predisposing factor (N = 14, 30%), followed by structural heart disease (N = 13, 28%) and intravenous drug abuse (N = 11, 24%).

The most common chief complaints among the patients with IE were fever (N = 24, 52%), dyspnea, and seizure, each in six (13%). Eighteen patients (39%) had a cardiac murmur. Thirty patients (71%) were systemic inflammatory response syndrome (SIRS) positive, and two (4%) had splenomegaly.

The etiology of IE remained unknown in 22 (48%). In the rest of the cases, methicillin-sensitive *Staphylococcus aureus* (MSSA) (N = 8, 17%) and methicillin-resistant *S. aureus* (MRSA) (N = 4, 9%) were the most common causative pathogens. Based on serology tests (Wright and 2- mercaptoethanol) brucella species caused IE in two cases.

According to Duke criteria, 21 patients (46%) had a definitive diagnosis of IE. Twelve patients (26%) were blood culture positive based on the criteria, and two (4%) had a biopsy consistent with IE.

Echocardiographic findings showed that 41 patients (89%) had intracardiac vegetation, two (4%) had new partial dehiscence of the prosthetic valve, and one (2%) had new valvular insufficiency. Most of the cases (N = 37, 80%) had single valve involvement, five (11%) had multiple valve involvement, and two (9%) had vegetation on the other parts of the heart (vegetation on the intracardiac device and right atrial wall each in one).

Mitral and aortic were the most commonly affected valves (N = 18, 39%, and N = 10, 22%, respectively), followed by the tricuspid valve (N = 8, 17%), simultaneous involvement of mitral and aortic valves (N = 4, 9%), and simultaneous involvement of aortic, pulmonary, and tricuspid valve (N = 1, 2%). Intravenous drug use (IVDU) was associated with a higher chance of right-sided IE, as compared to no IVDU patients (77.8% vs. 9.1%, p < 0.001, odds ratio: 35, 95% confidence interval: 3.7 to 425.0). There was no statistically significant association between the IVDU patients and *S. aureus* (80% vs. 50%, p = 0.24, OR: 4, 95% confidence interval: 0.28 to 221.13).

The frequency of minor Duke criteria was as follows: fever (N = 40, 87%), vascular symptoms (N=14, 30%), evidence of minor culture (N = 9, 20%), and immunological symptoms (N = 6, 13%).

Of 46 patients with IE, 25 (54%) experienced complications (Table 2). The most frequent

**Table 1 (continued).** Characteristics of the patients with infective endocarditis.

Characteristic         Total, N = 46           Chief complaint (%)         Fever         24 (52)           Peyer         24 (52)           Dyspnea         6 (13)           Seizure         6 (13)           Loss of consciousness         3 (7)           Knee joint pain         2 (4)           Weakness and lethargy         2 (4)           Fever and petechia         1 (2)           Clinical features (%)         Cardiae murmur         18 (39)           Splenomegaly         2 (4)         Respiratory rate (per minute), N = 38           < 20	infective endocarditis.	
Fever 24 (52) Dyspnea 6 (13) Seizure 6 (13) Seizure 6 (13) Loss of consciousness 3 (7) Knee joint pain 2 (4) Weakness and lethargy 2 (4) Pelvic pain 2 (4) Fever and petechia 1 (2) Clinical features (%) Cardiac murmur 18 (39) Splenomegaly 2 (4) Respiratory rate (per minute), N = 38 < 20 23 (7) 20 to 30 8 (21) > 30 6 (16) Intubated 1 (3) Heart rate (per minute), N = 42 < 100 22 (52) More than 100 22 (52) More than 100 20 (48) Laboratory features Urine analysis, N = 34 Leukocyturia 1 11 (32) Hematuria 2 17 (50) Proteinuria 3 8 (24) Complete blood count, N = 41 Platelet Fewer than 150 × 10°/L 18 (44) 150 to 450 × 10°/L 1 (2) Leukocyte Normal 18 (44) Leukocytosis 4 23 (56) Positive systemic inflammatory response syndrome 5, N = 42 Etiology, % Unknown 22 (48) Methicillin-resistant Staphylococcus aureus 4 (9) Vancomycin-resistant Entercococus 3 (7) Viridans streptococci 2 (4) Pseudomonas aeruginosa 2 (4) Brucella species 2 (4) Escherichia coli 8 (7) Group B Streptococcus 1 (2) Laudida species 1 (2) Laudida species 1 (2) Number of affected valves (%) Single 37 (80) Multiple 5 (11) No valve involvement 4 (9) Affected valves, N = 417 Mitral valve 18 (44) Aortic valve 10 (24) Tricuspid valve 10 (24) Tricuspid valve 10 (24) Tricuspid valve 10 (24) Africted valves, N = 417 Mitral and Aortic valve 10 (24) Tricuspid valve 10 (24) Tricuspid valve 10 (24) Arricuspid		<b>Total, N = 46</b>
Dyspnea   Seizure   Seiz	•	
Seizure	Fever	, ,
Loss of consciousness  Knee joint pain  Knee joint pain  2 (4)  Weakness and lethargy  Pelvic pain  2 (4)  Pever and petechia  1 (2)  Clinical features (%)  Cardiac murmur  18 (39)  Splenomegaly  2 (4)  Respiratory rate (per minute), N = 38  < 20  20 to 30  8 (21)  > 30  6 (16)  Intubated  Heart rate (per minute), N = 42  < 100  Meart rate (per minute), N = 42  < 100  Laboratory features  Urine analysis, N = 34  Leukocyturia¹  Hematuria²  Hematuria²  Horotieniuria³  8 (24)  Complete blood count, N = 41  Platelet  Fewer than 150 × 10°/L  Leukocytur  Normal  18 (44)  Leukocytosis⁴  Positive systemic inflammatory response syndrome¹, N = 42  Etiology, %  Unknown  Methicillin-sensitive Staphylococcus aureus  Methicillin-resistant Staphylococcus aureus  Methicillin-resistant Enterococcus  Viridans streptococci  2 (4)  Pseudomonas aeruginosa  Brucella species⁶  2 (4)  Escherichia coli  Group B Streptococcus  Candida species  1 (2)  Number of affected valves (%)  Single  37 (80)  Multiple  No valve involvement  4 (9)  Affected valves, N = 417  Mitral valve  Mitral valve  1 (2)  Mitral and Aortic valves  Aortic, pulmonary, and tricuspid valves  involvement  1 (2)  Leukoric, pulmonary, and tricuspid valves  involvement  1 (2)	• •	6 (13)
Knee joint pain   2 (4)     Weakness and lethargy   2 (4)     Pelvic pain   2 (4)     Fever and petechia   1 (2)     Clinical features (%)     Cardiac murmur   18 (39)     Splenomegaly   2 (4)     Respiratory rate (per minute), N = 38     < 20	Seizure	6 (13)
Weakness and lethargy       2 (4)         Pelvic pain       2 (4)         Fever and petechia       1 (2)         Clinical features (%)       1 (2)         Cardiac murmur       18 (39)         Splenomegaly       2 (4)         Respiratory rate (per minute), N = 38       20         20 to 30       8 (21)         > 30       6 (16)         Intubated       1 (3)         Heart rate (per minute), N = 42       22 (52)         < 100	Loss of consciousness	3 (7)
Pelvic pain 2 (4) Fever and petechia 1 (2) Clinical features (%) Cardiac murmur 18 (39) Splenomegaly 2 (4) Respiratory rate (per minute), N = 38 < 20 23 (7) 20 to 30 8 (21) > 30 6 (16) Intubated 1 (3) Heart rate (per minute), N = 42 < 100 22 (52) More than 100 20 (48) Laboratory features Urine analysis, N = 34 Leukocyturia 1 11 (32) Hematuria 17 (50) Proteinuria 8 (24) Complete blood count, N = 41 Platelet Fewer than 150 × 10°/L 18 (44) 150 to 450 × 10°/L 1 (2) Leukocyte Normal 18 (44) Leukocytosis 4 23 (56) Positive systemic inflammatory response syndrome , N = 42 Etiology, % Unknown 22 (48) Methicillin-resistant Enterococcus sureus 4 (9) Vancomycin-resistant Enterococcus 3 (7) Viridans streptococci 2 (4) Pseudomonas aeruginosa 2 (4) Brucella species 4 (24) Escherichia coli 8 (7) Group B Streptococcus (12) Candida species 1 (2) Number of affected valves (%) Single 37 (80) Multiple 5 (11) No valve involvement 4 (9) Affected valves, N = 417 Mitral valve 18 (44) Aortic valve 10 (24) Tricuspid valve 8 (20) Mitral and Aortic valves involvement 4 (10) Aortic, pulmonary, and tricuspid valves involvement 1 (2) Indicator of the control	Knee joint pain	2 (4)
Fever and petechia	Weakness and lethargy	2 (4)
Fever and petechia	Pelvic pain	2 (4)
Clinical features (%)   Cardiac murmur	*	
Cardiac murmur   Splenomegaly   Sp		- (-)
Splenomegaly   Respiratory rate (per minute), N = 38	· ·	18 (39)
Respiratory rate (per minute), N = 38     < 20		
\$\begin{array}{c c c c c c c c c c c c c c c c c c c		2(1)
20 to 30	- · ·	23 (7)
> 30		` '
Intubated   1 (3)		- 1
Heart rate (per minute), N = 42		
Section   Sect		1 (3)
More than 100       20 (48)         Laboratory features       Urine analysis, N = 34         Leukocyturia¹       11 (32)         Hematuria²       17 (50)         Proteinuria³       8 (24)         Complete blood count, N = 41       1         Platelet       18 (44)         Fewer than 150 × 10°/L       18 (44)         150 to 450 × 10°/L       1 (2)         Leukocyte       1 (2)         Normal       18 (44)         Leukocytesis⁴       23 (56)         Positive systemic inflammatory response syndrome³, N = 42       30 (71)         Etiology, %       Unknown         Methicillin-sensitive Staphylococcus aureus       8 (17)         Methicillin-resistant Staphylococcus aureus       4 (9)         Vancomycin-resistant Enterococcus       3 (7)         Viridans streptococci       2 (4)         Pseudomonas aeruginosa       2 (4)         Brucella species⁶       2 (4)         Escherichia coli       8 (7)         Group B Streptococcus       1 (2)         Candida species       2 (4)         Brucella species⁶       2 (4)         Escherichia coli       8 (7)         Group B Streptococcus       1 (2)         N	· · · · · · · · · · · · · · · · · · ·	22 (52)
Laboratory features         Urine analysis, N = 34         Leukocyturia¹       11 (32)         Hematuria²       17 (50)         Proteinuria³       8 (24)         Complete blood count, N = 41       19 latelet         Fewer than 150 × 10°/L       18 (44)         150 to 450 × 10°/l       22 (54)         More than 450 × 10°/L       1 (2)         Leukocyte       18 (44)         Normal       18 (44)         Leukocytosis⁴       23 (56)         Positive systemic inflammatory response syndrome⁵, N = 42       30 (71)         Etiology, %       10 long the systemic start		, ,
Urine analysis, N = 34  Leukocyturia <sup>1</sup> 11 (32)  Hematuria <sup>2</sup> 17 (50)  Proteinuria <sup>3</sup> 8 (24)  Complete blood count, N = 41  Platelet  Fewer than 150 × 10 <sup>9</sup> /L 18 (44)  150 to 450 × 10 <sup>9</sup> /L 1(2)  Leukocyte  Normal 18 (44)  Leukocytosis <sup>4</sup> 23 (56)  Positive systemic inflammatory response syndrome <sup>5</sup> , N = 42  Etiology, %  Unknown 22 (48)  Methicillin-sensitive Staphylococcus aureus 8 (17)  Methicillin-resistant Staphylococcus aureus 4 (9)  Vancomycin-resistant Enterococcus 3 (7)  Viridans streptococci 2 (4)  Pseudomonas aeruginosa 2 (4)  Brucella species <sup>6</sup> 2 (4)  Escherichia coli 8 (7)  Group B Streptococcus 1 (2)  Candida species 1 (2)  Number of affected valves (%)  Single 37 (80)  Multiple 5 (11)  No valve involvement 4 (9)  Affected valves, N = 41 <sup>7</sup> Mitral valve 18 (44)  Aortic valve 10 (24)  Tricuspid valve 8 (20)  Mitral and Aortic valves 4 (10)  Aortic, pulmonary, and tricuspid valves involvement 1 (2)		20 (48)
Leukocyturia		
Hematuria   17 (50)     Proteinuria   8 (24)     Complete blood count, N = 41     Platelet     Fewer than 150 × 10 9/L   18 (44)     150 to 450 × 10 9/L   1 (2)     Leukocyte     Normal   18 (44)     Leukocytesis   23 (56)     Positive systemic inflammatory response syndrome   N = 42     Etiology, %     Unknown   22 (48)     Methicillin-sensitive Staphylococcus aureus   4 (9)     Vancomycin-resistant Staphylococcus aureus   4 (9)     Vancomycin-resistant Enterococcus   2 (4)     Pseudomonas aeruginosa   2 (4)     Brucella species   2 (4)     Escherichia coli   8 (7)     Group B Streptococcus   1 (2)     Candida species   1 (2)     Number of affected valves (%)     Single   37 (80)     Multiple   5 (11)     No valve involvement   4 (9)     Affected valves, N = 417     Mitral valve   18 (44)     Aortic valve   10 (24)     Tricuspid valve   8 (20)     Mitral and Aortic valves   4 (10)     Aortic, pulmonary, and tricuspid valves     involvement   1 (2)		
Proteinuria <sup>3</sup> 8 (24)  Complete blood count, N = 41  Platelet  Fewer than 150 × 10 <sup>9</sup> /L 18 (44) 150 to 450 × 10 <sup>9</sup> /L 1 (2)  Leukocyte  Normal 18 (44)  Leukocytosis <sup>4</sup> 23 (56)  Positive systemic inflammatory response syndrome <sup>5</sup> , N = 42  Etiology, %  Unknown 22 (48)  Methicillin-sensitive Staphylococcus aureus 8 (17)  Methicillin-resistant Staphylococcus aureus 4 (9)  Vancomycin-resistant Enterococcus 3 (7)  Viridans streptococci 2 (4)  Pseudomonas aeruginosa 2 (4)  Brucella species <sup>6</sup> 2 (4)  Escherichia coli 8 (7)  Group B Streptococcus (8)  Single 37 (80)  Multiple 5 (11)  No valve involvement 4 (9)  Affected valves, N = 41 <sup>7</sup> Mitral valve 18 (44)  Aortic valve 10 (24)  Tricuspid valve 8 (20)  Mitral and Aortic valves (410)  Aortic, pulmonary, and tricuspid valves involvement 1 (2)		11 (32)
Complete blood count, N = 41Platelet $18 (44)$ Fewer than $150 \times 10^9$ /L $18 (44)$ $150$ to $450 \times 10^9$ /L $1 (2)$ Leukocyte $1 (2)$ Normal $18 (44)$ Leukocytosis <sup>4</sup> $23 (56)$ Positive systemic inflammatory response syndrome <sup>5</sup> , N = $42$ $30 (71)$ Etiology, % $30 (71)$ Unknown $22 (48)$ Methicillin-sensitive Staphylococcus aureus $4 (9)$ Vancomycin-resistant Staphylococcus aureus $4 (9)$ Vancomycin-resistant Enterococcus $3 (7)$ Viridans streptococci $2 (4)$ Pseudomonas aeruginosa $2 (4)$ Brucella species $2 (4)$ Escherichia coli $8 (7)$ Group B Streptococcus $1 (2)$ Candida species $1 (2)$ Number of affected valves (%) $37 (80)$ Single $37 (80)$ Multiple $5 (11)$ No valve involvement $4 (9)$ Affected valves, N = $41^7$ Mitral valve $18 (44)$ Aortic valve $10 (24)$ Tricuspid valve $8 (20)$ Mitral and Aortic valves $4 (10)$ Aortic, pulmonary, and tricuspid valves involvement $1 (2)$	Hematuria <sup>2</sup>	17 (50)
Platelet Fewer than $150 \times 10^9/L$	Proteinuria <sup>3</sup>	8 (24)
Fewer than $150 \times 10^9/L$ 18 (44) $150$ to $450 \times 10^9/L$ 22 (54)         More than $450 \times 10^9/L$ 1 (2)         Leukocyte       18 (44)         Normal       18 (44)         Leukocytosis <sup>4</sup> 23 (56)         Positive systemic inflammatory response       30 (71)         syndrome <sup>5</sup> , N = 42       2         Etiology, %       22 (48)         Methicillin-sensitive Staphylococcus aureus       8 (17)         Methicillin-resistant Staphylococcus aureus       4 (9)         Vancomycin-resistant Enterococcus       3 (7)         Viridans streptococci       2 (4)         Pseudomonas aeruginosa       2 (4)         Brucella species <sup>6</sup> 2 (4)         Escherichia coli       8 (7)         Group B Streptococcus       1 (2)         Candida species       1 (2)         Number of affected valves (%)       37 (80)         Single       37 (80)         Multiple       5 (11)         No valve involvement       4 (9)         Affected valves, N = 41 <sup>7</sup> Mitral valve       18 (44)         Aortic valve       10 (24)         Tricuspid valve       8 (20)         Mitral and Aortic valves </td <td>Complete blood count, N = 41</td> <td></td>	Complete blood count, N = 41	
150 to $450 \times 10^9$ /I       22 (54)         More than $450 \times 10^9$ /L       1 (2)         Leukocyte       18 (44)         Normal       18 (44)         Leukocytosis <sup>4</sup> 23 (56)         Positive systemic inflammatory response syndrome <sup>5</sup> , N = 42       30 (71)         Etiology, %       Vunknown         Methicillin-sensitive Staphylococcus aureus       8 (17)         Methicillin-resistant Staphylococcus aureus       4 (9)         Vancomycin-resistant Enterococcus       3 (7)         Viridans streptococci       2 (4)         Pseudomonas aeruginosa       2 (4)         Brucella species <sup>6</sup> 2 (4)         Escherichia coli       8 (7)         Group B Streptococcus       1 (2)         Candida species       1 (2)         Number of affected valves (%)       5 (11)         Single       37 (80)         Multiple       5 (11)         No valve involvement       4 (9)         Affected valves, N = 41 <sup>7</sup> Mitral valve       18 (44)         Aortic valve       10 (24)         Tricuspid valve       8 (20)         Mitral and Aortic valves       4 (10)         Aortic, pulmonary, and tricuspid valves       1 (2) <td>Platelet</td> <td></td>	Platelet	
More than $450 \times 10^9/L$	Fewer than $150 \times 10^9$ /L	18 (44)
More than $450 \times 10^9/L$	$150 \text{ to } 450 \times 10^9 / 1$	22 (54)
Leukocyte         18 (44)           Leukocytosis <sup>4</sup> 23 (56)           Positive systemic inflammatory response syndrome <sup>5</sup> , N = 42         30 (71)           Etiology, %         Unknown           Methicillin-sensitive Staphylococcus aureus         8 (17)           Methicillin-resistant Staphylococcus aureus         4 (9)           Vancomycin-resistant Enterococcus         3 (7)           Viridans streptococci         2 (4)           Pseudomonas aeruginosa         2 (4)           Brucella species <sup>6</sup> 2 (4)           Escherichia coli         8 (7)           Group B Streptococcus         1 (2)           Candida species         1 (2)           Number of affected valves (%)         5 (11)           Single         37 (80)           Multiple         5 (11)           No valve involvement         4 (9)           Affected valves, N = 41 <sup>7</sup> Mitral valve         18 (44)           Aortic valve         10 (24)           Tricuspid valve         8 (20)           Mitral and Aortic valves         4 (10)           Aortic, pulmonary, and tricuspid valves         1 (2)	More than $450 \times 10^9/L$	, ,
Normal         18 (44)           Leukocytosis⁴         23 (56)           Positive systemic inflammatory response syndrome⁵, N = 42         30 (71)           Etiology, %         ***           Unknown         22 (48)           Methicillin-sensitive Staphylococcus aureus         8 (17)           Methicillin-resistant Staphylococcus aureus         4 (9)           Vancomycin-resistant Enterococcus         3 (7)           Viridans streptococci         2 (4)           Pseudomonas aeruginosa         2 (4)           Brucella species⁶         2 (4)           Escherichia coli         8 (7)           Group B Streptococcus         1 (2)           Candida species         1 (2)           Number of affected valves (%)         **           Single         37 (80)           Multiple         5 (11)           No valve involvement         4 (9)           Affected valves, N = 417         **           Mitral valve         18 (44)           Aortic valve         10 (24)           Tricuspid valve         8 (20)           Mitral and Aortic valves         4 (10)           Aortic, pulmonary, and tricuspid valves involvement         1 (2)	Leukocyte	. ,
Leukocytosis <sup>4</sup> 23 (56)         Positive systemic inflammatory response syndrome <sup>5</sup> , N = 42       30 (71)         Etiology, % <ul> <li>Unknown</li> <li>22 (48)</li> </ul> Methicillin-sensitive Staphylococcus aureus       8 (17)         Methicillin-resistant Staphylococcus aureus       4 (9)         Vancomycin-resistant Enterococus       3 (7)         Viridans streptococci       2 (4)         Pseudomonas aeruginosa       2 (4)         Brucella species <sup>6</sup> 2 (4)         Escherichia coli       8 (7)         Group B Streptococcus       1 (2)         Candida species       1 (2)         Number of affected valves (%)       37 (80)         Single       37 (80)         Multiple       5 (11)         No valve involvement       4 (9)         Affected valves, N = 41 <sup>7</sup> Mitral valve       18 (44)         Aortic valve       10 (24)         Tricuspid valve       8 (20)         Mitral and Aortic valves       4 (10)         Aortic, pulmonary, and tricuspid valves involvement       1 (2)	·	18 (44)
Positive systemic inflammatory response syndrome <sup>5</sup> , N = 42         30 (71)           Etiology, %         22 (48)           Unknown         22 (48)           Methicillin-sensitive Staphylococcus aureus         8 (17)           Methicillin-resistant Staphylococcus aureus         4 (9)           Vancomycin-resistant Enterococcus         3 (7)           Viridans streptococci         2 (4)           Pseudomonas aeruginosa         2 (4)           Brucella species <sup>6</sup> 2 (4)           Escherichia coli         8 (7)           Group B Streptococcus         1 (2)           Candida species         1 (2)           Number of affected valves (%)         37 (80)           Single         37 (80)           Multiple         5 (11)           No valve involvement         4 (9)           Affected valves, N = 41 <sup>7</sup> 4 (9)           Mitral valve         18 (44)           Aortic valve         10 (24)           Tricuspid valve         8 (20)           Mitral and Aortic valves         4 (10)           Aortic, pulmonary, and tricuspid valves involvement         1 (2)		, ,
syndrome <sup>5</sup> , N = 42         30 (71)           Etiology, %         22 (48)           Unknown         22 (48)           Methicillin-sensitive Staphylococcus aureus         8 (17)           Methicillin-resistant Staphylococcus aureus         4 (9)           Vancomycin-resistant Enterococcus         3 (7)           Viridans streptococci         2 (4)           Pseudomonas aeruginosa         2 (4)           Brucella species <sup>6</sup> 2 (4)           Escherichia coli         8 (7)           Group B Streptococcus         1 (2)           Candida species         1 (2)           Number of affected valves (%)         37 (80)           Single         37 (80)           Multiple         5 (11)           No valve involvement         4 (9)           Affected valves, N = 41 <sup>7</sup> Mitral valve         18 (44)           Aortic valve         10 (24)           Tricuspid valve         8 (20)           Mitral and Aortic valves         4 (10)           Aortic, pulmonary, and tricuspid valves involvement         1 (2)		25 (00)
Etiology, %         22 (48)           Unknown         22 (48)           Methicillin-sensitive Staphylococcus aureus         8 (17)           Methicillin-resistant Staphylococcus aureus         4 (9)           Vancomycin-resistant Enterococcus         3 (7)           Viridans streptococci         2 (4)           Pseudomonas aeruginosa         2 (4)           Brucella species <sup>6</sup> 2 (4)           Escherichia coli         8 (7)           Group B Streptococcus         1 (2)           Candida species         1 (2)           Number of affected valves (%)         37 (80)           Single         37 (80)           Multiple         5 (11)           No valve involvement         4 (9)           Affected valves, N = 41 <sup>7</sup> Mitral valve         18 (44)           Aortic valve         10 (24)           Tricuspid valve         8 (20)           Mitral and Aortic valves         4 (10)           Aortic, pulmonary, and tricuspid valves involvement         1 (2)	syndrome <sup>5</sup> $N = 42$	30 (71)
Unknown 22 (48)  Methicillin-sensitive Staphylococcus aureus 8 (17)  Methicillin-resistant Staphylococcus aureus 4 (9)  Vancomycin-resistant Enterococcus 3 (7)  Viridans streptococci 2 (4)  Pseudomonas aeruginosa 2 (4)  Brucella species <sup>6</sup> 2 (4)  Escherichia coli 8 (7)  Group B Streptococcus 1 (2)  Candida species 1 (2)  Number of affected valves (%)  Single 37 (80)  Multiple 5 (11)  No valve involvement 4 (9)  Affected valves, N = 41 <sup>7</sup> Mitral valve 18 (44)  Aortic valve 10 (24)  Tricuspid valve 8 (20)  Mitral and Aortic valves 4 (10)  Aortic, pulmonary, and tricuspid valves involvement 1 (2)		
Methicillin-sensitive Staphylococcus aureus         8 (17)           Methicillin-resistant Staphylococcus aureus         4 (9)           Vancomycin-resistant Enterococcus         3 (7)           Viridans streptococci         2 (4)           Pseudomonas aeruginosa         2 (4)           Brucella species <sup>6</sup> 2 (4)           Escherichia coli         8 (7)           Group B Streptococcus         1 (2)           Candida species         1 (2)           Number of affected valves (%)         5           Single         37 (80)           Multiple         5 (11)           No valve involvement         4 (9)           Affected valves, N = 41 <sup>7</sup> Mitral valve         18 (44)           Aortic valve         10 (24)           Tricuspid valve         8 (20)           Mitral and Aortic valves         4 (10)           Aortic, pulmonary, and tricuspid valves         1 (2)		22 (48)
Methicillin-resistant Staphylococcus aureus       4 (9)         Vancomycin-resistant Enterococcus       3 (7)         Viridans streptococci       2 (4)         Pseudomonas aeruginosa       2 (4)         Brucella species <sup>6</sup> 2 (4)         Escherichia coli       8 (7)         Group B Streptococcus       1 (2)         Candida species       1 (2)         Number of affected valves (%)       5         Single       37 (80)         Multiple       5 (11)         No valve involvement       4 (9)         Affected valves, N = 41 <sup>7</sup> Mitral valve       18 (44)         Aortic valve       10 (24)         Tricuspid valve       8 (20)         Mitral and Aortic valves       4 (10)         Aortic, pulmonary, and tricuspid valves       1 (2)		- · · · · · ·
Vancomycin-resistant Enterococcus       3 (7)         Viridans streptococci       2 (4)         Pseudomonas aeruginosa       2 (4)         Brucella species <sup>6</sup> 2 (4)         Escherichia coli       8 (7)         Group B Streptococcus       1 (2)         Candida species       1 (2)         Number of affected valves (%)       5         Single       37 (80)         Multiple       5 (11)         No valve involvement       4 (9)         Affected valves, N = 41 <sup>7</sup> Mitral valve       18 (44)         Aortic valve       10 (24)         Tricuspid valve       8 (20)         Mitral and Aortic valves       4 (10)         Aortic, pulmonary, and tricuspid valves involvement       1 (2)		. ` `
Viridans streptococci       2 (4)         Pseudomonas aeruginosa       2 (4)         Brucella species <sup>6</sup> 2 (4)         Escherichia coli       8 (7)         Group B Streptococcus       1 (2)         Candida species       1 (2)         Number of affected valves (%)       37 (80)         Multiple       5 (11)         No valve involvement       4 (9)         Affected valves, N = 41 <sup>7</sup> Mitral valve       18 (44)         Aortic valve       10 (24)         Tricuspid valve       8 (20)         Mitral and Aortic valves       4 (10)         Aortic, pulmonary, and tricuspid valves involvement       1 (2)		* *
Pseudomonas aeruginosa         2 (4)           Brucella species <sup>6</sup> 2 (4)           Escherichia coli         8 (7)           Group B Streptococcus         1 (2)           Candida species         1 (2)           Number of affected valves (%)         37 (80)           Single         37 (80)           Multiple         5 (11)           No valve involvement         4 (9)           Affected valves, N = 41 <sup>7</sup> Mitral valve         18 (44)           Aortic valve         10 (24)           Tricuspid valve         8 (20)           Mitral and Aortic valves         4 (10)           Aortic, pulmonary, and tricuspid valves involvement         1 (2)		* *
Brucella species <sup>6</sup> 2 (4)         Escherichia coli       8 (7)         Group B Streptococcus       1 (2)         Candida species       1 (2)         Number of affected valves (%)       37 (80)         Single       37 (80)         Multiple       5 (11)         No valve involvement       4 (9)         Affected valves, N = 41 <sup>7</sup> Mitral valve       18 (44)         Aortic valve       10 (24)         Tricuspid valve       8 (20)         Mitral and Aortic valves       4 (10)         Aortic, pulmonary, and tricuspid valves involvement       1 (2)	•	` '
Escherichia coli       8 (7)         Group B Streptococcus       1 (2)         Candida species       1 (2)         Number of affected valves (%)       37 (80)         Single       37 (80)         Multiple       5 (11)         No valve involvement       4 (9)         Affected valves, N = 41 <sup>7</sup> Mitral valve       18 (44)         Aortic valve       10 (24)         Tricuspid valve       8 (20)         Mitral and Aortic valves       4 (10)         Aortic, pulmonary, and tricuspid valves involvement       1 (2)		\ /
Group B Streptococcus       1 (2)         Candida species       1 (2)         Number of affected valves (%)       37 (80)         Single       37 (80)         Multiple       5 (11)         No valve involvement       4 (9)         Affected valves, N = 417         Mitral valve       18 (44)         Aortic valve       10 (24)         Tricuspid valve       8 (20)         Mitral and Aortic valves       4 (10)         Aortic, pulmonary, and tricuspid valves involvement       1 (2)	·	
Candida species       1 (2)         Number of affected valves (%)       37 (80)         Single       37 (80)         Multiple       5 (11)         No valve involvement       4 (9)         Affected valves, N = 417         Mitral valve       18 (44)         Aortic valve       10 (24)         Tricuspid valve       8 (20)         Mitral and Aortic valves       4 (10)         Aortic, pulmonary, and tricuspid valves involvement       1 (2)		
Number of affected valves (%)           Single         37 (80)           Multiple         5 (11)           No valve involvement         4 (9)           Affected valves, N = 417         18 (44)           Mitral valve         18 (24)           Aortic valve         10 (24)           Tricuspid valve         8 (20)           Mitral and Aortic valves         4 (10)           Aortic, pulmonary, and tricuspid valves involvement         1 (2)	Group B Streptococcus	1 (2)
Single         37 (80)           Multiple         5 (11)           No valve involvement         4 (9)           Affected valves, N = 417           Mitral valve         18 (44)           Aortic valve         10 (24)           Tricuspid valve         8 (20)           Mitral and Aortic valves         4 (10)           Aortic, pulmonary, and tricuspid valves involvement         1 (2)		1(2)
Single         37 (80)           Multiple         5 (11)           No valve involvement         4 (9)           Affected valves, N = 417           Mitral valve         18 (44)           Aortic valve         10 (24)           Tricuspid valve         8 (20)           Mitral and Aortic valves         4 (10)           Aortic, pulmonary, and tricuspid valves involvement         1 (2)	Number of affected valves (%)	
No valve involvement $4 (9)$ Affected valves, $N = 41^7$ Mitral valve $18 (44)$ Aortic valve $10 (24)$ Tricuspid valve $8 (20)$ Mitral and Aortic valves $4 (10)$ Aortic, pulmonary, and tricuspid valves involvement $1 (2)$		37 (80)
Affected valves, $N = 41^7$ Mitral valve 18 (44) Aortic valve 10 (24) Tricuspid valve 8 (20) Mitral and Aortic valves 4 (10) Aortic, pulmonary, and tricuspid valves involvement 1 (2)	Multiple	5 (11)
Affected valves, $N = 41^7$ Mitral valve $18 (44)$ Aortic valve $10 (24)$ Tricuspid valve $8 (20)$ Mitral and Aortic valves $4 (10)$ Aortic, pulmonary, and tricuspid valves involvement $1 (2)$	No valve involvement	
Mitral valve 18 (44) Aortic valve 10 (24) Tricuspid valve 8 (20) Mitral and Aortic valves 4 (10) Aortic, pulmonary, and tricuspid valves involvement 1 (2)	_	` /
Aortic valve 10 (24) Tricuspid valve 8 (20) Mitral and Aortic valves 4 (10) Aortic, pulmonary, and tricuspid valves involvement 1 (2)		18 (44)
Tricuspid valve 8 (20)  Mitral and Aortic valves 4 (10)  Aortic, pulmonary, and tricuspid valves involvement 1 (2)		* *
Mitral and Aortic valves 4 (10) Aortic, pulmonary, and tricuspid valves 1 (2)		, ,
Aortic, pulmonary, and tricuspid valves involvement 1 (2)		* *
involvement 1 (2)		7 (10)
involvement		1 (2)
		(IDE), 2 E-4

1 Leukocyte count above 5 per High power field (HPF); 2 Erythrocyte count above 5 per HPF; 3 Based on the dipstick test; 4 Leukocyte count above 11 thousand per microliter; 5 If any two of the following were present: temperature over 38 or under 36 degrees Celsius, a heart rate greater than 90 beats per minute, a respiratory rate greater than 20 breaths per minute, white blood cells more than 12 thousand per microliter or less than 4 thousand per microliter; 6 The diagnosis was made based on serology (Wright and 2-mercaptoethanol); 7 Forty-two patients had valvular involvement, of whom one patient with single valve involvement had no data regarding the affected valve.

complications were lung infarction, acute heart failure, and neurologic involvement ( $N=5,\ 11$  for each), followed by acute kidney injury ( $N=4,\ 9\%$ ). In addition, in-hospital mortality was 33% (N=15).

Twenty-six patients (57%) out of 46, required surgical treatment. Of these patients, 18 (39%) underwent surgery in our hospital.

Univariable analysis revealed no significant association between poor outcome (death) and different factors (Table 3).

## **Discussion**

We evaluated 46 cases of IE in an eight-year period with a median age of 42 years (interquartile range 31 to 58.3). Other studies conducted in Iran and its neighboring countries demonstrated a mean age range of 45 to 48.1 [11,15–17]. However, in some cases, the mean age in high-income countries was higher [18–20]. Consistent with previous studies, our results revealed that IE more frequently affected males (N = 29, 63%) than females [18,19,21]. Regarding past investigations in Iran, this rate was about 60% [11,22].

The risk factors of IE are significantly associated with the socio-economic level of countries [6]. For instance, rheumatic heart disease (RHD) is the leading risk factor in low-income countries. On the other hand, in high-income countries, the significant risk factors are prosthetic valves and intracardiac devices [6,7]. Our study showed that the most common predisposing cardiac conditions were the presence of prosthetic valves and intracardiac devices, which were present in nearly one-third of the subjects. However, only three of our patients had a history of RHD, which was lower than those in middle to high-income settings [23–25]. Since numerous patients missed academic education, this might reveal a relationship between the effect of socio-economic level and the incidence of IE. Therefore, designing studies with larger sample sizes and analyzing the possible relationship between the data will help to understand the social risk factors of IE and the prognosis of patients.

IE diagnosis should be considered in patients with compatible clinical features even without a known underlying disease [18,26]. In the current study, about 17% of patients had no former known predisposing factors for IE. Same to our results, prior studies revealed that fever was the main symptom of IE patients [11,18,27]. The prevalence of splenomegaly in our study was much lesser than in another investigation in Iran [22]. The possible reason for the lower number of patients with splenomegaly may be due to patients visiting our center in the early stages of the disease.

Since about half of the patients had negative cultures, the causing pathogen remained anonymous.

**Table 2.** Complications, treatment, and outcome of patients with infective endocarditis.

N = 46
5 (11)
5 (11)
5 (11)
4 (9)
3 (7)
2 (4)
2 (4)
1 (2)
1(2)
20 (44)
18 (39)
6 (13)
5 (11)
7 (15)
8 (17)
0 (17)
15 (33)
22 (48)
9 (20)

<sup>1</sup> The complications either occurred during hospitalization or on admission; 2 Due to thrombocytopenia; 3 The data regarding the type of surgery were not available in seven patients; 4 These were due to patient unwillingness and poor candidacy for surgical treatment.

Table 3. Comparing characteristics of survived and dead patients with infective endocarditis.

	Survived $^{1}$ (N = 22)	<b>Death (N = 15)</b>	<i>p</i> value
Age (years), median (25th percentile to 75th percentile)	39 (30.3 to 44)	43.5 (36 to 72)	0.14
Elderly (≥ 60 years, %)	2 (9)	4 (27)	0.15
Gender, male (%)	17 (77)	10 (67)	0.48
Symptom duration (days), median (25th percentile to 75th percentile)	10 (3 to 20)	12 (3 to 60)	0.52
Diabetes mellitus (%)	2 (9)	2 (13)	0.68
Acute heart failure (%)	2 (9)	4 (27)	0.20
Neurologic involvement (%)	3 (14)	2 (13)	0.98
Staphylococcus aureus etiology (%)	6/10 (60)	4/9 (44)	0.50
Septic emboli (%)	8 (36)	4 (27)	0.54
Need for surgical treatment (%)	11 (50)	8 (53)	0.84
1371			

<sup>1</sup> Nine patients were excluded from the analysis because they left the hospital before treatment completion.

The frequency of negative culture was considerably higher than in several high-income countries (10-20%) [20,28,29]. This could be due to laboratory errors which may be a consequence of inappropriate laboratory techniques or specimen preparation. In addition, it might be because of antibiotics overuse before obtaining the blood culture. Notably, because our center is a tertiary hospital, several patients had been referred from other centers after antibiotics consumption. Additionally, in some cases, non-bacterial pathogens generate culture-negative IE.

The main pathogen in our study was S. aureus which was predominant in studies of high-income countries (26.1%) [6]. The amount of antibiotic consumption, the differences in antibiotic resistance, and the epidemiology of common pathogens in each region would result in variations in microbial profiles [6,8]. The most predominant pathogens of IE are staphylococci and streptococci in high-income and lowincome countries, respectively [6,8]. The prevalence of IE caused by staphylococci species has increased in several countries, while the prevalence of streptococcal species infection declined remarkably. The growing trend of staphylococcal endocarditis might be related to the increasing use of intravenous drugs, intravenous catheters, the aging population, and patients on dialysis [6,30,31].

Additionally, the proportion of IE cases caused by MRSA in our study was higher than the regions with low MRSA frequency (with a proportion of 3.7%-7%) [17,21]. Nonetheless, this proportion is lower than in some countries, including the United States (17.5%) and Qatar (11%) [18,32]. However, this comparison should be made with caution due to the high prevalence of negative culture in our study. In this regard, efforts to improve diagnostic tests help determine the microbial profile of each region and design antibiograms for national guidelines. Furthermore, investigation through the microbial profile, especially regions harboring antibiotic resistance, is essential in the case of selecting the proper empirical antibiotic treatment [21,24].

More than 95% of our patients had echocardiographic manifestations. Regarding our limitations in microbiological diagnostic tools, echocardiography is essential for the diagnosis of IE in our center. Due to a lower rate of negative cultures in high-income countries, microbiology tests play a significant role in diagnosing IE [20].

In agreement with other studies [18,24], mitral and aortic were the most commonly affected valves, involving 39% and 22% of patients, respectively.

However, other studies highlighted the aortic valve as the most commonly involved valve [22,27,29]. The rate of tricuspid valve involvement among our patients was far higher (N = 8, 20%) than in other studies [18,27,29]. It could be due to a higher frequency of intravenous drug users in this study. Our results revealed that IVDU was related to a higher odd of right-sided IE compared to no IVDU patients (OR: 35, 95% CI: 3.7 to 425), which had a medium to a large effect [14].

In-hospital mortality (N = 11, 24%) was higher compared to previous studies [18,23]. It might be due to some patients' discontent with surgical treatment or delayed diagnosis of IE. Our findings showed no significant relation between mortality and different factors. It could be due to the small sample size of our study, which resulted in low power status. Based on prior studies, aging, *S. aureus* etiology, septic embolism, diabetes mellitus, heart failure, neurologic event, and cardiac abscess were some risk factors associated with a higher risk of mortality [23,24,29,33].

The current study had several limitations. First, the retrospective design of this study and lack of follow-up caused limited information in terms of long-term patients' outcome. Second, the details of medical records were not accessible for all the subjects. Last but not least, regarding the small sample size of our study, the detection of significant associations and drawing conclusions that could be applied to a larger population is difficult.

## **Conclusions**

The present study showed that the median age of IE was relatively low in our center. The primary cardiac predisposing factors were prosthetic valves or intracardiac devices. Furthermore, a considerable proportion of patients were culture negative; among culture-positive cases, *S. aureus* was the predominant identified pathogen. Additionally, a higher frequency of right-sided IE was associated with IVDU. The rate of patients harboring unfavorable outcomes was high, declaring the importance of enhancing laboratory tests, proper and early treatment procedures, and eliminating underlying disease factors.

# Acknowledgements

We acknowledge support from the vice-chancellery for research at Mashhad University of Medical Sciences.

#### **Authors' contributions**

AS: Data collection, Investigation, Writing - Review & Editing; MS: Data collection, Investigation, Writing - Review & Editing; RJ: Data analysis, Investigation, Data

collection; AAH: Conceptualization, Methodology, Supervision, Writing - Review & Editing. All authors read and approved the final version.

#### References

- Kiefer TL, Bashore TM (2012) Infective endocarditis: a comprehensive overview. Rev Cardiovasc Med 13: e105-20. doi: 10.3909/ricm0633.
- Yang X, Chen H, Zhang D, Shen L, An G, Zhao S (2022) Global magnitude and temporal trend of infective endocarditis, 1990-2019: results from the Global Burden of Disease Study. Eur J Prev Cardiol 29: 1277–1286. doi: 10.1093/eurjpc/zwab184.
- Williams ML, Doyle MP, McNamara N, Tardo D, Mathew M, Robinson B (2021) Epidemiology of infective endocarditis before versus after change of international guidelines: a systematic review. Ther Adv Cardiovasc Dis 15: 17539447211002688. doi: 10.1177/17539447211002687.
- Dayer MJ, Jones S, Prendergast B, Baddour LM, Lockhart PB, Thornhill MH (2015) Incidence of infective endocarditis in England, 2000-13: a secular trend, interrupted time-series analysis. Lancet 385: 1219–1228. doi: 10.1016/S0140-6736(14)62007-9.
- Pedretti RFE, Iliou MC, Israel CW, Abreu A, Miljoen H, Corra U, Stellbrink C, Gevaert AB, Theuns DA, Piepoli MF, Reibis R (2021) Comprehensive multicomponent cardiac rehabilitation in cardiac implantable electronic devices recipients: a consensus document from the European Association of Preventive Cardiology (EAPC; Secondary prevention and rehabilitation section) and European Heart Rhythm Association (EHRA). Eur J Prev Cardiol 28: 1736–1752. doi: 10.1093/eurjpc/zwaa121.
- Ambrosioni J, Hernandez-Meneses M, Téllez A, Pericàs J, Falces C, Tolosana JM, Vidal B, Almela M, Quintana E, Llopis J, Moreno A (2017) The changing epidemiology of infective endocarditis in the twenty-first century. Curr Infect Rep 19: 21. doi: 10.1007/s11908-017-0574-9.
- Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta JP, Del Zotti F, Dulgheru R, El Khoury G, Erba PA, Iung B, Miro JM (2015) 2015 ESC guidelines for the management of infective endocarditis: the task force for the management of infective endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J 36: 3075–3128. doi: 10.1714/2214.23904.
- 8. Njuguna B, Gardner A, Karwa R, Delahaye F (2017) Infective endocarditis in low- and middle-income countries. Cardiol Clin 35: 153–163. doi: 10.1016/j.ccl.2016.08.011.
- Nunes MC, Gelape CL, Ferrari TC (2010) Profile of infective endocarditis at a tertiary care center in Brazil during a sevenyear period: prognostic factors and in-hospital outcome. Int J Infect Dis 14: e394-8. doi: 10.1016/j.ijid.2009.06.024.
- Tornos P, Gonzalez-Alujas T, Thuny F, Habib G (2011) Infective endocarditis: the European viewpoint. Curr Probl Cardiol 36: 175–222. doi: 10.1016/j.cpcardiol.2011.03.004.
- Faraji R, Behjati-Ardakani M, Moshtaghioun SM, Kalantar SM, Namayandeh SM, Soltani M, Zandi H, Firoozabadi AD, Banizi NT, Kahtooie FQ, Banaei M (2017) Evaluation of epidemiological, clinical, and microbiological features of definite infective endocarditis. GMS Hyg Infect Control 12: Doc01. doi: 10.3205/dgkh000286.

- Pecoraro AJ, Doubell AF (2020) Infective endocarditis in South Africa. Cardiovasc Diagn Ther 10: 252–261. doi: 10.21037/cdt.2019.06.03.
- Pecoraro AJ, Herbst PG, Doubell AF (2022) Infective endocarditis in Africa: an urgent call for more data. Lancet Glob Health 10: e8–e9. doi: 10.1016/S2214-109X(21)00489-7
- 14. Olivier J, Bell ML (2013) Effect sizes for 2 × 2 contingency tables. PloS One 8: e58777. doi: 10.1371/journal.pone.0058777.
- Ali SS, Qureshi IA, Ayaz A, Arshad A, Farhad A, Jamil B, Sohail MR (2022) Etiology, clinical characteristics, and outcome of infective endocarditis: 10-year experience from a tertiary care center in Pakistan. Monaldi Arch Chest Dis 92. doi: 10.4081/monaldi.2022.2212.
- 16. Al Abri SS, Zahedi FI, Kurup PJ, Al-Jardani AK, Beeching NJ (2014) The epidemiology and outcomes of infective endocarditis in a tertiary care hospital in Oman. J Infect Public Health 7: 400–406. doi: 10.1016/j.jiph.2014.04.004.
- Barry M, Bari SA, Akhtar MY, Al Nahdi F, Erlandez R, Al Khushail A, Al Hebaishi Y (2021) Clinical and microbiological characteristics of infective endocarditis at a cardiac center in Saudi Arabia. J Epidemiol Glob Health 11: 435–443. doi: 10.1007/s44197-021-00013-5.
- Zaqout A, Mohammed S, Thapur M, Al-Soub H, Al-Maslamani MA, Al-Khal A, Omrani AS (2020) Clinical characteristics, microbiology, and outcomes of infective endocarditis in Qatar. Qatar Med J 2020: 24. doi: 10.5339/qmj.2020.24.
- Habib G, Erba PA, Iung B, Donal E, Cosyns B, Laroche C, Popescu BA, Prendergast B, Tornos P, Sadeghpour A, Oliver L (2019) Clinical presentation, aetiology and outcome of infective endocarditis. Results of the ESC-EORP EURO-ENDO (European infective endocarditis) registry: a prospective cohort study. Eur Heart J 40: 3222–3232. doi: 10.1093/eurheartj/ehz620.
- Cresti A, Chiavarelli M, Scalese M, Nencioni C, Valentini S, Guerrini F, d'Aiello I, Picchi A, De Sensi F, Habib G (2017) Epidemiological and mortality trends in infective endocarditis, a 17-year population-based prospective study. Cardiovasc Diagn Ther 7: 27–35. doi: 10.21037/cdt.2016.08.09.
- Papakonstantinou PE, Samonis G, Andrianaki AM, Christofaki M, Dimopoulou D, Papadakis J, Gikas A, Kofteridis DP (2018) Epidemiology, microbiological and clinical features, treatment, and outcomes of infective endocarditis in Crete, Greece. Infect Chemother 50: 21–28. doi: 10.3947/ic.2018.50.1.21.
- 22. Hajihossainlou B, Heidarnia MA, Sharif Kashani B (2013) Changing pattern of infective endocarditis in Iran: A 16 years survey. Pak J Med Sci 29: 85–90. doi: 10.12669/pjms.291.2682.
- Alsamarrai A, Saavedra C, Bryce A, Dimalapang E, Leversha A, Briggs S, Wilson N, Wheeler M (2022) Infective endocarditis in patients with rheumatic heart disease: a single-centre retrospective comparative study. N Z Med J 135: 62–73.
- 24. Giannitsioti E, Pefanis A, Gogos C, Lekkou A, Dalekos GN, Gatselis N, Georgiadou S, Nikou P, Vrettou A, Rigopoulos A, Tryfonopoulos C (2021) Evolution of epidemiological characteristics of infective endocarditis in Greece. Int J Infect Dis 106: 213–220. doi: 10.1016/j.ijid.2021.03.009.
- Krčméry V, Hricak V, Fischer V, Mrazova M, Brnova J, Hulman M, Outrata R, Bauer F, Kalavsky E, Babela R, Mikolasova G (2019) Etiology, risk factors and outcome of

- 1003 cases of infective endocarditis from a 33-year national survey in the Slovak Republic: an increasing proportion of elderly patients. Neuro Endocrinol Lett 39: 544–549.
- 26. Juson ADS, Delgado J (2019) The clinical profile of nativevalve infective endocarditis in a tertiary hospital in the Philippines: a twelve-year retrospective study. Int J Infect Dis 79: 47–48. doi: 10.1016/j.ijid.2018.11.128.
- 27. Wu Z, Chen Y, Xiao T, Niu T, Shi Q, Xiao Y (2020) Epidemiology and risk factors of infective endocarditis in a tertiary hospital in China from 2007 to 2016. BMC Infect Dis 20: 428. doi: 10.1186/s12879-020-05153-w.
- 28. Firiana L, Siswanto BB, Yonas E, Prakoso R, Pranata R (2020) Factors affecting mortality in patients with blood-culture negative infective endocarditis. Int J Angiol 29: 12–18. doi: 10.1055/s-0039-3402744.
- Kong WKF, Salsano A, Giacobbe DR, Popescu BA, Laroche C, Duval X, Schueler R, Moreo A, Colonna P, Piper C, Calvo-Iglesias F (2022) Outcomes of culture-negative vs. culture-positive infective endocarditis: the ESC-EORP EURO-ENDO registry. Eur Heart J 43: 2770–2780. doi: 10.1093/eurhearti/ehac307.
- Büchi A, Hoffmann M, Zbinden S, Atkinson A, Sendi P (2018)
   The Duke minor criterion "predisposing heart condition" in native valve infective endocarditis - a systematic review. Swiss Med Wkly 148: w14675. doi: 10.4414/smw.2018.14675.
- 31. Cahill TJ, Baddour LM, Habib G, Hoen B, Salaun E, Pettersson GB, Schäfers HJ, Prendergast BD (2017) Challenges in

- infective endocarditis. J Am Coll Cardiol 69: 325–344. doi: 10.1016/j.jacc.2016.10.066.
- 32. Mostaghim AS, Lo HYA, Khardori N (2017) A retrospective epidemiologic study to define risk factors, microbiology, and clinical outcomes of infective endocarditis in a large tertiary-care teaching hospital. SAGE Open Med 5: 2050312117741772. doi: 10.1177/2050312117741772.
- Zhang X, Jin F, Lu Y, Ni F, Xu Y, Xia W (2022) Clinical characteristics and risk factors for in-hospital mortality in 240 cases of infective endocarditis in a tertiary hospital in China: a retrospective study. Infect Drug Resist 15: 3179–3189. doi: 10.2147/IDR.S362601.

## **Corresponding author**

Ali Akbar Heydari, MD Associate Professor Research Center for Infection Control & Hand Hygiene and Department of Infectious Diseases,

Imam Reza Hospital, Imam Reza Square,

Mashhad, Iran. 9137913316

Tel: +989155139807

ORCID: 0000-0003-4954-7624 Email: heydariaa@mums.ac.ir

**Conflict of interests:** No conflict of interests is declared.